Mipasetamab 产品活性：Mipasetamab 是一种靶向 AXL 的 IgG1κ 抗体，AXL 是一种酪氨酸激酶受体，或者是 TAM 受体 (TAM Receptor)。 Mipasetamab 参与 ADCT-601 (Mipasetamab uzoptirine) 的合成，这是一种 AXL 靶向的抗体-活性分子偶联物 (ADC)。ADCT-601 具有抗肿瘤作用。 产品来源： https://www.medchemexpress.cn/mipasetamab.html 研究领域：Antibody-drug Conjugate/ADC Related | Protein Tyrosine Kinase/RTK 作用靶点：ADC Antibody | TAM Receptor In Vitro: ADCT-601 (0.02-9.29 nM; 5 d) shows cytotoxicity on AXL-positive SN12C cells but ont AXL-negative Karpas-299 cells. ADCT-601 (0.83 nM; 2-36 h) increases the level of DNA interstrand cross-links time-dependently in SN12C cells. In Vivo: ADCT-601 (3 mg/kg, 6 mg/kg; i.v.; single dose) is safety and tolerability in non-tumor-bearing male Sprague-Dawley rats. ADCT-601 (1 mg/kg; i.v.; once daily for 60 days) shows potent and sustained antitumor activity for mouse in both MDA-MB-231 TNBC xenograft model and SN12C renal cancer xenograft model. ADCT-601 (0.075, 0.15, or 0.3 mg/kg; i.v.; once daily for 45 days) also dose-dependently in a pancreatic cancer PDX model (PAXF1657) with heterogeneous AXL expression. 相关产品：Trastuzumab | Cabozantinib | Gilteritinib | Bemcentinib | Sacituzumab | Daratumumab | 2-D08 | Dubermatinib | Enfortumab | LDC1267 | BMS 777607 | Datopotamab | UNC2250 | UNC2541 | Gemtuzumab | Inebilizumab | Glembatumumab | Glesatinib hydrochloride | Zanzalintinib | Belantamab | UNC569 | Polatuzumab | Tamnorzatinib | Tisotumab | Upifitamab | Ningetinib | RU-301 | SGI-7079 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。